Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies

Clinical Cancer Research

Volumn 19, Issue 17, 2013, Pages 4792-4800

  Besser, Michal J ^a,b   Shapira Frommer, Ronnie ^a   Itzhaki, Orit ^a   Treves, Avraham J ^a   Zippel, Douglas B ^a   Levy, Daphna ^a   Kubi, Adva ^a   Shoshani, Noa ^a   Zikich, Dragoslav ^a   Ohayon, Yaara ^a   Ohayon, Daniel ^c   Shalmon, Bruria ^a   Markel, Gal ^a,b   Yerushalmi, Ronit ^a   Apter, Sara ^a   Ben Nun, Alon ^a   Ben Ami, Eytan ^a   Shimoni, Avichai ^a   Nagler, Arnon ^a   Schachter, Jacob ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ECOLE CENTRALE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FLUDARABINE; INTERLEUKIN 2; IPILIMUMAB; LACTATE DEHYDROGENASE;

ADOPTIVE TRANSFER; ADULT; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CD8+ T LYMPHOCYTE; CONFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART FAILURE; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; IMMUNOTHERAPY; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG CONGESTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; REMISSION; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

ADOPTIVE TRANSFER; ADULT; AGED; ANTIBODIES, MONOCLONAL; CELL- AND TISSUE-BASED THERAPY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING;

EID: 84883472041     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0380     Document Type: Article

References (27)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J of Med 2011;364:2507-16.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
3. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18: 2039-47
4. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
5. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
6. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 2011; 8:577-85.
7. Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, et al. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 2011;34:212-20.
8. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26: 332-42. (Pubitemid 36858717)
9. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, et al. Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go? Nat Clin Pract Oncol 2006;3:668-81. (Pubitemid 44843125)
10. Dudley ME, Wunderlich JR, Robbins PF, Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4. (Pubitemid 35231542)
11. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005;26:111-7.
12. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9.
13. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor in filtration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010;16:2646-55.
14. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Speci fic lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-in filtrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012;18:6758-70.
15. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57. (Pubitemid 46218728)
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
17. Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994;12:1475-83. (Pubitemid 24206248)
18. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, et al. Minimally-cultured or selected autologous tumor infiltrating lymphocytes following a lymphodepleting chemotherapy Regimen in Metastatic Melanoma Patients. J Immunother 2009;32:415-23.
19. Jin J, Sabatino M, Somerville RJ, Wilson JR, Dudley ME, Stroncek DF, et al. Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 2012;35:283-92.
20. Schallmach E, Sareli R, Besser MJ, Leipsiger S, Hardan I, Treves AJ, et al. Collection of large-scale expanded lymphocyte cultures for adoptive immunotherapy using a COBE spectra apheresis machine. J Immunother 2008;31:563-8.
21. Deichmann M, Kahle B, Moser K, Wacker J, Wüst K. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. J Cancer 2004;91:699-702. (Pubitemid 39141627)
22. Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009;45:1807-14.
23. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, et al.Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34. (Pubitemid 351264344)
24. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 2008;26:624-33. (Pubitemid 351918588)
25. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16. (Pubitemid 29318842)
26. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps8.
27. Yang JC. T cell adoptive therapy for cancer: Translating the science. Presented at the American Association of Cancer Research Special Conference on Tumor Immunology; 2012 Dec 2-5; Miami, FL.